- Alfonso Rueda, accompanied by the conselleiro de Sanidade, Julio García Comesaña, valued the work of the Santiago de Compostela Health Research Institute, confirming its commitment to health and scientific research. They visited the laboratories of the GenVip research group, led by Federico Martinón Torres.
Santiago de Compostela, May 18, 2022. The Health Research Institute of Santiago de Compostela today received a visit from the president of the Xunta de Galicia, Alfonso Rueda Valenzuela; and the Minister of Health, Julio García Comesaña, who visited the laboratory facilities of the GenVip research group, directed by Federico Martinón Torres.
Alfonso Rueda thanked during this visit, one of the first public acts carried out as president of the Galician Government, the work of the IDIS researchers and stressed that it is their work that makes this “pioneering center” one of the most recognized internationally in the field of infectious diseases and childhood vaccines.
IDIS, promoting excellent research
The Health Research Institute of Santiago de Compostela is a markedly translational biomedical research center that takes advantage of the synergies of the Santiago de Compostela University Hospital Complex (CHUS) and the Santiago de Compostela University (USC) to drive and promote research of excellence, scientific and technological knowledge and its subsequent transfer to the productive sector. Teaching and training are also promoted from IDIS and always with a clear objective: to improve the health of the population.
The IDIS was established on January 31, 2008, through a collaboration agreement between the Ministry of Health, the Galician Health Service and the University of Santiago de Compostela and has been accredited since March 2010, as a research center of the National System of Health, by the Carlos III Health Institute, renewing said accreditation in May 2015 and March 2020.
Currently, 1,161 people are integrated into 99 IDIS research groups, organized in turn into 6 research areas: Oncology, Genetics and Systems Biology, Endocrinology, Neurosciences, Platforms and Methodology, and Inflammation.
GenVip is a research group specialized in the pediatric area dedicated to the study of infectious diseases, which develops clinical trials on vaccines. The team has 45 researchers with a cumulative scientific impact factor of over 5,000, generating more than 20 publications each year, and participating at the highest level in the front line of research.
This group, which is part of the Health Research Institute of Santiago, collaborates with international institutions, such as Imperial College London, Genomic Institute of Singapore, Oxford Gene Technology, Ospidale Pediatico Bambino Gesú, PENTA Fondazione, Oxford University, Bristol University, etc, and also at national level with Consejo Superior de Investigaciones Científicas (CSIC), the Universitat Autònoma de Barcelona (UAB), the Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), or the Direcció Clínica Territorial de Malalties Infeccioses i Salut Internacional (Badalona), among others.